Enliven Therapeutics (ELVN) Competitors $21.23 -0.89 (-4.02%) As of 02:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELVN vs. ACLX, AKRO, MENS, KYMR, CRNX, NAMS, VKTX, LNTH, MIRM, and ADMAShould you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Arcellx (ACLX), Akero Therapeutics (AKRO), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Lantheus (LNTH), Mirum Pharmaceuticals (MIRM), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Enliven Therapeutics vs. Its Competitors Arcellx Akero Therapeutics Jyong Biotech Kymera Therapeutics Crinetics Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Lantheus Mirum Pharmaceuticals ADMA Biologics Enliven Therapeutics (NASDAQ:ELVN) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership. Is ELVN or ACLX more profitable? Enliven Therapeutics has a net margin of 0.00% compared to Arcellx's net margin of -329.93%. Enliven Therapeutics' return on equity of -29.15% beat Arcellx's return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -29.15% -27.88% Arcellx -329.93%-43.04%-27.41% Which has more volatility and risk, ELVN or ACLX? Enliven Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Do analysts recommend ELVN or ACLX? Enliven Therapeutics presently has a consensus target price of $41.20, indicating a potential upside of 93.15%. Arcellx has a consensus target price of $113.08, indicating a potential upside of 31.78%. Given Enliven Therapeutics' higher possible upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67Arcellx 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.86 Does the media prefer ELVN or ACLX? In the previous week, Enliven Therapeutics and Enliven Therapeutics both had 3 articles in the media. Arcellx's average media sentiment score of 0.80 beat Enliven Therapeutics' score of 0.34 indicating that Arcellx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcellx 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of ELVN or ACLX? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, ELVN or ACLX? Enliven Therapeutics has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$89.02M-$2.00-10.67Arcellx$56.98M83.53-$107.35M-$3.42-25.09 SummaryEnliven Therapeutics beats Arcellx on 8 of the 15 factors compared between the two stocks. Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELVN vs. The Competition Export to ExcelMetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27B$2.64B$6.14B$10.63BDividend YieldN/A57.79%5.72%4.85%P/E Ratio-10.6823.9929.2427.24Price / SalesN/A594.61494.13189.00Price / CashN/A27.2425.8230.35Price / Book3.365.3912.496.67Net Income-$89.02M$33.06M$3.32B$276.25M7 Day Performance6.12%2.01%2.07%0.10%1 Month Performance12.51%10.96%8.78%3.84%1 Year Performance-26.11%-1.53%63.73%33.07% Enliven Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELVNEnliven Therapeutics1.9399 of 5 stars$21.23-4.0%$41.20+94.1%-23.7%$1.26BN/A-10.6250ACLXArcellx2.6545 of 5 stars$85.18-1.2%$112.69+32.3%-10.4%$4.73B$107.94M-24.9480AKROAkero Therapeutics3.7583 of 5 stars$53.90+0.4%$73.38+36.1%+72.6%$4.31BN/A-26.9530MENSJyong BiotechN/A$55.75+0.1%N/AN/A$4.24BN/A0.0031Positive NewsGap UpKYMRKymera Therapeutics1.2129 of 5 stars$59.32-1.0%$61.26+3.3%+30.4%$4.24B$47.07M-17.08170Analyst ForecastCRNXCrinetics Pharmaceuticals4.4159 of 5 stars$44.09-0.8%$74.45+68.9%-28.2%$4.16B$1.04M-10.74210Positive NewsNAMSNewAmsterdam Pharma3.0388 of 5 stars$36.86-0.8%$42.00+13.9%+95.5%$4.15B$45.56M-22.754News CoverageAnalyst ForecastVKTXViking Therapeutics4.0081 of 5 stars$33.93+0.1%$86.42+154.7%-48.7%$3.81BN/A-22.1220Upcoming EarningsLNTHLantheus4.5931 of 5 stars$54.35-0.4%$74.50+37.1%-51.5%$3.68B$1.53B14.41700MIRMMirum Pharmaceuticals4.1064 of 5 stars$72.60+0.6%$76.50+5.4%+85.1%$3.65B$336.89M-60.00140ADMAADMA Biologics3.6697 of 5 stars$14.87+2.2%$27.67+86.1%-6.9%$3.55B$426.45M17.31530Positive News Related Companies and Tools Related Companies Arcellx Competitors Akero Therapeutics Competitors Jyong Biotech Competitors Kymera Therapeutics Competitors Crinetics Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Viking Therapeutics Competitors Lantheus Competitors Mirum Pharmaceuticals Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELVN) was last updated on 10/21/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
